Budget Amount *help |
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2014: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Fiscal Year 2013: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
Outline of Final Research Achievements |
The treatment of patients with TNBC has been challenging due to the absence of these molecular targets and the heterogeneity of the disease. The aim of our study is to elucidate the clinical importance of the expression of E-cadherin and vimentin in breast cancer.The elevated expression of vimentin contributes to the aggressive phenotype and poor prognosis in TNBC and basal-like breast cancer. Vimentin expression might be useful as a biomarker for the prognosis of TNBC. Also, co-expression of E-cadherin and vimentin seems to be associated with the most aggressive phenotype in breast cancer, and positive E-cadherin expression may not always play roles for tumor suppression. Vimentin and related molecule will be a good target to control the invasion and metastasis in TNBC.
|